Monitoring plasma levels of factor Xa inhibitors: how, why and when?

References

• Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl.), e44S–e88S (2012).
   PubMed Web of Science ®Google Scholar
• Montoya RC, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Adv. Hematol. 2012, 856341 (2012).
   PubMedGoogle Scholar
• Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am. J. Cardiol. 110(3), 453–460 (2012).
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L et al.; Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease position paper. J. Am. Coll. Cardiol. 59(16), 1413–1425 (2012).
   PubMed Web of Science ®Google Scholar
• Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl.), e24S–e43S (2012).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin. Investig. Drugs 11(3), 397–407 (2002).
   PubMed Web of Science ®Google Scholar
• Roehrig S, Straub A, Pohlmann J et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J. Med. Chem. 48(19), 5900–5908 (2005).
   PubMed Web of Science ®Google Scholar
• Jeske WP, Walenga JM, Samama MM, Hoppensteadt D, Mayuga M, Fareed J. Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Blood Coagul. Fibrinolysis 22(3), 206–210 (2011).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Bara L, Samama MM, Fareed J. Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions. Semin. Thromb. Hemost. 11(2), 100–107 (1985).
   PubMed Web of Science ®Google Scholar
• Mani H, Rohde G, Stratmann G et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb. Haemost. 108(1), 191–198 (2012).
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther. Drug Monit. 32(6), 673–679 (2010).
   PubMed Web of Science ®Google Scholar
• Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb. Haemost. 104(5), 1078–1079 (2010).
   PubMed Web of Science ®Google Scholar
• Samama MM, Martinoli JL, LeFlem L et al. Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor. Thromb. Haemost. 103(4), 815–825 (2010).
   PubMed Web of Science ®Google Scholar
• Castro-López V, Murray B, Harris LF, O’Donnell JS, Killard AJ. Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin. Blood Coagul. Fibrinolysis 23(1), 98–103 (2012).
   PubMed Web of Science ®Google Scholar
• Haas S. Facts and artefacts of coagulation assays for factor Xa inhibitors. Thromb. Haemost. 103(4), 686–688 (2010).
   PubMed Web of Science ®Google Scholar
• Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin. Thromb. Hemost. 38(2), 178–184 (2012).
   PubMed Web of Science ®Google Scholar
• Asmis LM, Alberio L, Angelillo-Scherrer A et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb. Res. 129(4), 492–498 (2012).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78(4), 412–421 (2005).
   PubMed Web of Science ®Google Scholar
• Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 3(3), 514–521 (2005).
   PubMed Web of Science ®Google Scholar
• Depasse F, Gerotziafas GT, Busson J, Van Dreden P, Samama MM. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J. Thromb. Haemost. 2(2), 346–348 (2004).
   PubMed Web of Science ®Google Scholar
• Samama MM, Contant G, Spiro TE et al.; Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb. Haemost. 107(2), 379–387 (2012).
   PubMed Web of Science ®Google Scholar
• Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J. Thromb. Thrombolysis 32(3), 267–271 (2011).
   PubMed Web of Science ®Google Scholar
• Harenberg J, Marx S, Weiss C, Krämer R, Samama MM, Schulman S; Subcommittee on Control of Anticoagulation of the ISTH. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J. Thromb. Haemost. 10(7), 1433–1436 (2012).
   PubMedGoogle Scholar
• Bara L, Mardiguian J, Samama M. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb. Res. 57(4), 585–592 (1990).
   PubMed Web of Science ®Google Scholar
• Perzborn E, Harwardt M, Samama MM. Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor. J. Thromb. Haemost. 7(Suppl. 2), Abstract PP-Mo-185 (2009).
   Google Scholar
• Harenberg J, Kraemer R. Measurement of the new anticoagulants. Thromb. Res. 129(Suppl. 1), S106–S113 (2012).
   Google Scholar
• Samama MM, Contant G, Spiro TE et al.; Rivaroxaban Prothrombin Time Field Trial Laboratories. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin. Appl. Thromb. Hemost. 18(2), 150–158 (2012).
   PubMed Web of Science ®Google Scholar
• Sinha U, Lin PH, Edwards ST et al. Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors. Arterioscler. Thromb. Vasc. Biol. 23(6), 1098–1104 (2003).
   PubMed Web of Science ®Google Scholar
• Hacquard M, Perrin J, Lelievre N, Vigneron C, Lecompte T. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography. Thromb. Res. 127(1), 29–34 (2011).
   PubMed Web of Science ®Google Scholar
• Samama MM. Interindividual variability of in vitro response to anticoagulants. Thromb. Res. 127(1), 1 (2011).
   PubMed Web of Science ®Google Scholar
• Ten Cate H. Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb. Haemost. 107(5), 803–805 (2012).
   PubMed Web of Science ®Google Scholar